Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 125
Single User License Price INR 8750
Corporate User License Price USD 375
Corporate User License Price INR 26250
Site License Price USD 250
Site License Price INR 17500
Request a Quote

Report Title

Neurocrine Biosciences Inc (NBIX)-Financial and Strategic SWOT Analysis Review

Quote Request for License Type
License Type Price  
Single User License USD 125
Site License USD 250
Enterprise Wide License USD 375
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Neurocrine Biosciences Inc (NBIX)-Financial and Strategic SWOT Analysis Review


Quote Request for License Type
License Type Price  
Single User License USD 125
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Neurocrine Biosciences Inc (NBIX)-Financial and Strategic SWOT Analysis Review

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Neurocrine Biosciences Inc (NBIX)-Financial and Strategic SWOT Analysis Review



Executive Summary

Neurocrine Biosciences Inc (NBIX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes new pharmaceutical products for the treatment of neurological and endocrine related diseases and disorders. The company's products help to treat disease conditions such as endometriosis, anxiety, depression, pain, and other neurological and endocrine related diseases and disorders. The lead candidates of the company include elagolix (Phase III), a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis; INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders completed its Phase III clinical trial; and Opicapone (Phase III), a catechol-o-methyltransferase inhibitor for Parkinson's disease patients. Other products in the pipeline include NBI-640756 and NBI-74788 both in Phase I. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc Key Recent Developments

Feb 14,2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017

Jan 06,2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer

Dec 21,2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down

Nov 02,2016: Neurocrine Biosciences Reports Third Quarter 2016 Results

Aug 03,2016: Neurocrine Biosciences Reports Second Quarter 2016 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Neurocrine Biosciences Inc-Key Facts 6

Neurocrine Biosciences Inc-Key Employees 7

Neurocrine Biosciences Inc-Key Employee Biographies 8

Neurocrine Biosciences Inc-Major Products and Services 10

Neurocrine Biosciences Inc-Pharmaceutical Pipeline Products Data 11

Neurocrine Biosciences Inc, Pipeline Products by Therapy Area 11

Neurocrine Biosciences Inc, Pipeline Products by Development Phase 11

Neurocrine Biosciences Inc-History 13

Neurocrine Biosciences Inc-Company Statement 16

Neurocrine Biosciences Inc-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Section 2-Company Analysis 20

Neurocrine Biosciences Inc-Business Description 20

Neurocrine Biosciences Inc-Corporate Strategy 21

Neurocrine Biosciences Inc-SWOT Analysis 22

SWOT Analysis-Overview 22

Neurocrine Biosciences Inc-Strengths 22

Neurocrine Biosciences Inc-Weaknesses 23

Neurocrine Biosciences Inc-Opportunities 24

Neurocrine Biosciences Inc-Threats 25

Neurocrine Biosciences Inc-Key Competitors 26

Section 3-Company Financial Ratios 27

Financial Ratios-Capital Market Ratios 27

Financial Ratios-Annual Ratios 28

Performance Chart 30

Financial Performance 30

Financial Ratios-Interim Ratios 31

Financial Ratios-Ratio Charts 32

Section 4-Company's Lifesciences Financial Deals and Alliances 33

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34

Neurocrine Biosciences Inc, Recent Deals Summary 35

Section 5-Company's Recent Developments 36

Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 36

Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 39

Dec 21, 2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down 40

Nov 02, 2016: Neurocrine Biosciences Reports Third Quarter 2016 Results 41

Aug 03, 2016: Neurocrine Biosciences Reports Second Quarter 2016 Results 44

May 20, 2016: Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors 46

May 05, 2016: Neurocrine Biosciences Reports First Quarter 2016 Results 47

Feb 11, 2016: Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 49

Section 6-Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Neurocrine Biosciences Inc, Pipeline Products by Therapy Area 11

Neurocrine Biosciences Inc, Pipeline Products by Development Phase 11

Neurocrine Biosciences Inc, Performance Chart (2012-2016) 30

Neurocrine Biosciences Inc, Ratio Charts 32

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 34

List of Tables

Neurocrine Biosciences Inc, Key Facts 6

Neurocrine Biosciences Inc, Key Employees 7

Neurocrine Biosciences Inc, Key Employee Biographies 8

Neurocrine Biosciences Inc, Major Products and Services 10

Neurocrine Biosciences Inc, Number of Pipeline Products by Development Stage 12

Neurocrine Biosciences Inc, History 13

Neurocrine Biosciences Inc, Subsidiaries 19

Neurocrine Biosciences Inc, Key Competitors 26

Neurocrine Biosciences Inc, Ratios based on current share price 27

Neurocrine Biosciences Inc, Annual Ratios 28

Neurocrine Biosciences Inc, Annual Ratios (Cont...1) 29

Neurocrine Biosciences Inc, Interim Ratios 31

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33

Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34

Neurocrine Biosciences Inc, Recent Deals Summary 35

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Prometheus Laboratories Inc, Pfizer Inc, Newron Pharmaceuticals SpA, Lundbeck LLC, GlaxoSmithKline Inc, Eli Lilly and Company, Auspex Pharmaceuticals Inc, AbbVie Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person